Table 2.
Demographic data of the matched (1:1) population
| CCPR (n = 80) |
ECPR (n = 80) |
SMD | p value | |
|---|---|---|---|---|
| Age, years | 57 ± 17 | 57 ± 14 | 0.01 | 0.93 |
| Male, n (%) | 49 (61) | 59 (74) | 0.08 | 0.13 |
| Witnessed CA, n (%) | 68 (85) | 70 (88) | 0.01 | 0.82 |
| Bystander CPR, n (%) | 59 (74) | 57 (71) | 0.05 | 0.86 |
| ROSC, n (%) | 30 (37) | 77 (96) | < 0.001 | |
| Time to ROSC, min | 54 ± 22 | 54 ± 20 | 0.004 | |
| Out-of-hospital CA | 50 (63) | 49 (61) | 0.03 | 1.00 |
| Non-cardiac origin CA | 44 (55) | 22 (28) | < 0.001 | |
| Initial rhythm | ||||
| VF/VT, n (%) | 23 (28) | 24 (30) | 0.09 | 0.93 |
| Asystole, n (%) | 38 (48) | 35 (44) | 0.10 | 0.75 |
| PEA, n (%) | 19 (24) | 21 (26) | 0.09 | 0.85 |
| Chronic heart failure, n (%) | 9 (11) | 19 (24) | 0.06 | |
| Hypertension, n (%) | 30 (38) | 30 (38) | 0.002 | 1.00 |
| Coronary artery disease, n (%) | 20 (25) | 33 (41) | 0.05 | |
| Diabetes, n (%) | 13 (16) | 10 (13) | 0.09 | 0.65 |
| COPD/asthma, n (%) | 11 (14) | 8 (10) | 0.08 | 0.63 |
| Neurological disease, n (%) | 6 (8) | 6 (8) | 0.001 | 1.00 |
| Chronic renal disease, n (%) | 7 (9) | 11 (14) | 0.45 | |
| Cirrhosis, n (%) | 5 (6) | 6 (8) | 1.00 | |
| Lactate on admission, mEq/L | 6.6 ± 5.1 | 8.8 ± 5.9 | < 0.001 | |
| MV, n (%) | 80 (100) | 80 (100) | 1.00 | |
| TTM, n (%) | 25 (31) | 70 (88) | < 0.001 | |
| Vasopressor therapy any time, n (%) | 49 (62) | 77 (96) | < 0.001 | |
| Inotropic therapy any time, n (%) | 34 (43) | 54 (68) | 0.002 | |
| CRRT, n (%) | 7 (9) | 20 (25) | 0.01 | |
| Coronary angiography, n (%) | 21 (27) | 35 (44) | 0.03 | |
| PTCA/CABG, n (%) | 12 (15) | 19 (24) | 0.22 | |
| Massive bleeding, n (%) | 13 (16) | 57 (71) | < 0.001 | |
| ICU stay, days | 1 [1–3] | 3 [1–10] | < 0.001 | |
| ICU survival, n (%) | 14 (18) | 18 (23) | 0.46* | |
| 3-month favorable neurological outcome, n (%) | 9 (11) | 17 (21) | 0.13* | |
ICU intensive care unit, CA cardiac arrest, CPR cardiopulmonary resuscitation, ROSC return of spontaneous circulation, VF/VT ventricular fibrillation/ventricular tachycardia, COPD chronic obstructive pulmonary disease, ECPR extracorporeal cardiopulmonary resuscitation, CRRT continuous renal replacement therapy, MV mechanical ventilation, PTCA percutaneous transluminal coronary angioplasty, CABG coronary artery bypass graft, TTM targeted temperature management, PEA pulseless electrical activity
*p value is reported for chi-square analysis